FL118 别名:FL-118; CAS# 151636-76-9
FL118是人类survivin表达的抑制剂,在p53野生型癌细胞中激活肿瘤抑制因子p53作为一种新型的MOA。FL118 与 DDX5 (p68) 结合,去磷酸化并降解 DDX5。
*AbMole所有产品仅供有资质的科研机构或医药企业进行科学研究或药证申报用途,不能被用于人体和任何其它用途。我们不向任何个人或非科研性质的机构提供产品和服务。
实验参考
蛋白/细胞实验
下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
浓度/溶剂体积/质量 |
1 mg |
5 mg |
10 mg |
1 mM |
2.5487 mL |
12.7434 mL |
25.4868 mL |
5 mM |
0.5097 mL |
2.5487 mL |
5.0974 mL |
10 mM |
0.2549 mL |
1.2743 mL |
2.5487 mL |
*吸湿的DMSO对产品的溶解度有显著影响,请使用新开封的DMSO;
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
动物实验
建议您制定动物给药及实验方案时,尽量参考已发表的相关实验文献(溶剂种类及配比众多,简单地溶解目的化合物,并不能解决动物给药依从性、体内生物利用度、组织分布等相关问题,未必能保证目的化合物在动物体内充分发挥生物学效用)。
体内实验的工作液,建议您现用现配,当天使用;如在配制过程中出现沉淀、析出现象,可以通过超声和(或)加热的方式助溶。
切勿一次性将产品全部溶解。
动物实验方案计算器
请在下面的计算器中,输入您的动物实验相关数据并点击计算,即可得到该实验的总需药量和工作液终浓度。
例如您给药剂量是10 mg/kg,平均每只动物的体重为20 g,每只动物的给药体积是100 μL,动物数量为20只,则该动物实验的总需药量为4 mg,工作液终浓度为2 mg/mL。
1:鉴于实验过程的损耗,建议您至少多配1-2只动物的量;
2:为该产品最终给药时的浓度。
其他相关的p53产品
参考文献
[1] Rabi Thangaiyan, et al. Am J Transl Res. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX
[2] Zhenxue Tang, et al. Life Sci. Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer
[3] Qi Weng, et al. Cancer Chemother Pharmacol. In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models
[4] Xiang Ling, et al. J Exp Clin Cancer Res. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
[5] Zhihong Yang, et al. Biosci Trends. FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
[6] Jin Wang, et al. Am J Transl Res. FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties
[7] David Westover, et al. Mol Cancer. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
[8] Xiang Ling, et al. Cancer Res. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX